



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

25 May 2015

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard ([eugeneb@sun.ac.za](mailto:eugeneb@sun.ac.za)), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally.

## Important notices

- Notice of Change to Key Dates in RFA-AG-16-005 "Characterization of Pro- and Anti-Geronic Proteins and Peptides (R01)" ([NOT-AG-15-007](#))
- Notice of Change to Key Dates in RFA-AG-16-012 Analyses of Human Datasets and Biospecimens to Characterize Aging-related Phenotypes Relationships to Circulating Polypeptides and Proteins that Reverse or Accelerate Aging Changes (R01)" ([NOT-AG-15-008](#))

### 1. Title: Martin Delaney Collaboratories for HIV Cure Research

**Letter of Intent due date:** November 7, 2015

**Hyperlink:** [\(RFA-AI-15-029\)](#)

**Type:** UM1

**Application Due Date:** December 7, 2015, by 5:00 PM local time of applicant organization

**Purpose:** The purpose of this Funding Opportunity Announcement (FOA) is to address the problem of HIV persistence in HIV-infected persons treated with suppressive antiretroviral drug regimens. This FOA will support coordinated basic, translational, and clinical research focused on developing strategies to achieve an HIV cure, defined as sustained HIV remission and/or eradication. The application must include at least one private sector entity to facilitate rapid translation of basic discovery research into clinical studies. Collaboratory research should be milestone-based and centered on specific innovative approaches spanning characterization and quantification of latent or persistent HIV-1 reservoirs, identification of therapeutic strategies that target these reservoirs and/or control viral rebound, and preclinical and clinical studies to test new single or combination strategies for an HIV cure.

**Budget:** Application budgets are limited to \$3.5 million Direct Costs per year, and should reflect the actual needs of the proposed project. The total project period may not exceed 5 years.

### 2. Title: Exploratory Clinical Trials of Novel Interventions for Mental Disorders

**Letter of Intent due date:** 30 days before the application due date

**Hyperlink:** [\(RFA-MH-16-406\)](#)

**Type:** R61/R33

**Application Due Date:** July 27, 2015; October 14, 2015; February 17, 2016; June 15, 2016; October 14, 2016, by 5:00 PM local time of applicant organization.

**Purpose:** The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. Studies of novel interventions include, but are not limited to behavioral, pharmacological, biologics-based, cognitive, device-based, interpersonal, physiological, or combined approaches. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the intervention's engagement of the therapeutic target, possibly followed by up to 3 years of support (R33 phase) for studies to replicate target engagement and relate change in the intervention target to functional or clinical effects. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders. Applications using only the R61 mechanism or only the R33 mechanism will not be accepted under this FOA. The R61 phase focuses on testing whether an objective measure can be used to assess intervention effects at the molecular, circuit or system level (i.e., target engagement), and may include testing hypotheses about the mechanism of action and/or preliminary evaluation of the clinical effect of manipulating the target. The specific activities and milestones appropriate for the R61 phase will depend on the type of intervention under study and its stage of development. - See more at: <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-16-406.htm> Applicants who already have sufficient preliminary data to progress to the R33 phase should apply directly to RFA-MH-16-400 "Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R33)". - See more at: <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-16-406.html>

**Budget:** Application budgets for the R61 phase and the R33 phase are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible.

### 3. Title: The Health of Sexual and Gender Minority (SGM) Populations

Letter of Intent due date: N/A

Hyperlink: [\(PA-15-261\)](#)  
[\(PA-15-263\)](#)  
[\(PA-15-262\)](#)

Type RO1  
R21  
RO3

**Application Due Date:** Standard dates apply, by 5:00 PM local time of applicant organization RO1: 5 June, 5 Oct, 5 Feb

**Purpose:** The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.

**Budget:** RO1: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. RO3: Direct costs are limited to \$100,000 direct costs over the 2-year period, with no more than \$50,000 in direct costs allowed in a single year.

#### **Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**UH2/UH3 - Phase Innovation Awards Cooperative Agreement:** Exploratory/Developmental Cooperative Agreement Phase I and II. To support the development of new research activities in categorical program areas (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R25 – NIH Education Projects:** used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

**R34 – Research Projects Planning Grant:** To provide support for the initial development of a clinical trial or research project, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design or experimental research designs and other essential elements of the study or project, such as the protocol, recruitment strategies, procedure manuals and collection of feasibility data.

**G11 Extramural Associate Research Development Award (EARDA) :** G11 Extramural Associate Research Development Award (EARDA) To provide funds to institutions eligible to participate in the NIH Extramural Associates Program for establishing or enhancing an office of sponsored research and for other research infrastructure needs.

Complete [Glossary and acronym list of NIH Terms](#)



Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: [Dr Christa de Vries](#) • Tel: 9838 • Email: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)